Skip to content
Clinical Trials – home
Therapeutic area

Congenital, familial and genetic disorders – page 17

  • 803 clinical trials
  • 311 recruiting
  • 375 conditions
  • 27 countries

Conditions in this area

375 conditions with trials, the busiest first

Clinical trials in Congenital, familial and genetic disorders

803 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

803 clinical trials

Study on the Safety and Effects of SPK-3006 for Adults with Late-Onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vanglusagene Ensiparvovec
  • Sponsor:Genentech Inc.

Study on Sildenafil for Adults with Single Ventricle Heart Condition Post-Fontan Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sildenafil
  • Sponsor:Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Study on the Effectiveness of INCB000928 for Patients with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:INCB000928
  • Sponsor:Incyte Corp.

Study on Gene Therapy for Severe Combined Immunodeficiency (SCID) Using ARTEGENE in Patients with Artemis Gene Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Containing The Human Dclre1C Gene
  • Sponsor:Assistance Publique Hopitaux De Paris

Imaging Study with 89Zr-Bevacizumab for Predicting Treatment Effects in Patients with NF2-Related Schwannomatosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab zirconium ZR-89
  • Sponsor:Leiden University Medical Center

Urethral valves

Recruiting

Study on Early Oxybutynin Treatment for Boys with Posterior Urethral Valves

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Oxybutynin
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Cystic fibrosis

Recruiting

Study on Improving Bone Health in Children with Cystic Fibrosis Using Cholecalciferol

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Colecalciferol
  • Sponsor:Fakultni Nemocnice V Motole

Study on the Safety of Inhaled Teicoplanin for Treating Staphylococcus aureus Infections in Cystic Fibrosis Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings SA

Hydrocele+1

Recruiting

Study on Sclerotherapy for Hydrocele and Spermatocele Using Lauromacrogol 400 and Ethanol in Adult Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ethanol, Anhydrous
  • Sponsor:Region Jamtland Harjedalen

Study of KK8123 for Adults with X-linked Hypophosphatemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:KK8123
  • Sponsor:Kyowa Kirin Inc.

Substances studied in this area

The therapies tested most often in Congenital, familial and genetic disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.